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CybridTumor microenvironment promotes mtDNA mutations. A number of these mutations will affect cell
metabolism and increase cell survival. These mutations are positively selected and contribute to other tumor
features, such as extracellular matrix remodeling and angiogenic processes, thus favoring metastases. Like
somatic mutations, although with less marked effects, some mtDNA population polymorphisms will affect
OXPHOS function, cell metabolism, and homeostasis. Thus, they could behave as inherited susceptibility
factors for cancer. However, in addition to epidemiological evidence, other more direct clues are required.
The cybrid approach can help to clarify this issue. This article is part of a Special Issue entitled: Bioenergetics
of Cancer.ergetics of Cancer.
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Carcinogenesis is a sequence of phenotypical adaptations to distinct
microenvironmental proliferation barriers. Multiple strategies can suc-
cessfully adapt to the same barrier, thus explaining the phenotypical and
genotypical heterogeneity of cancer populations [1]. Therefore, the
number of cancer genes is large. Thus, the cancer genome is composed
of a few commonlymutated genes andmany infrequentlymutated genes
that function in a relatively small number of pathways that cooperate to
induce disease. The pathway components that are altered in individual
tumors vary widely, suggesting that mutations in many genes in the
pathway can have similar effects on tumor cell growth. Thus, the
pathways, rather than individual genes, dictate the course of tumorigen-
esis [2]. Multiple genetic changes seem to be required in carcinogenesis
[3], and different tumors can showdistinctmutations. Thismeans that no
particular mutation in cancer-associated nuclear genes is sufﬁcient or
necessary to cause cancer,whencancer is consideredas a class of diseases.
The same considerations must be taken into account when mutations in
mtDNA genes are analyzed in relation with the tumoral phenotype.
Therefore, we will not address whether mtDNA mutations and OXPHOS
dysfunction are required for tumor development, but we will focus on
whether mtDNA mutations can inﬂuence the tumor phenotype.
Large families with multiple cases of early-onset cancer affecting
several generations provide clear evidence that inherited factors areimportant causes of cancer. Family history is an important risk factor
in almost all cancers, but most family cancers are not caused by
mutations in the rare relatively high-risk tumor-associated genes, so
lower-risk genes must be present [4]. In this review, because mtDNA
is inherited by maternal lineage, we will explore whether or not there
is a maternally inherited predisposition to cancer. In other words, is
there a mtDNA-inherited susceptibility to cancer?
2. Cytoplasmic suppression of tumor formation
2.1. Hybrids
A possible contribution of extrachromosomal factors to tumorige-
nicity was suggested after the observation that tumorigenicity was
still suppressed in some human (ﬁbroblast)–mouse (malignant
melanoma) hybrid clones after segregation of all detectable human
chromosomes derived from the nontumorigenic cell [5]. The radio-
sensitivity of this factor suggested that it was a genetic entity. But,
because many previous studies on human–mouse hybrids had shown
that those hybrids where the human chromosomes had been
preferentially eliminated did not contain human mtDNA, the authors
excluded mtDNA as the extrachromosomal factor. However, the fact
that these hybrids can retain human mtDNA for many generations [6]
and that mtDNA is the only cytoplasmic genetic factor in mammalian
cells suggested that mtDNA was the tumorigenicity suppressor.
2.2. Heteroplasmic cybrids
The effect of cytoplasm upon the expression of tumorigenicity can
be evaluated by the cybrid approach. Cybrids are cell lines originating
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[7]. Cell fragments with mitochondria but without a nucleus, such as
platelets [8] or synaptosomes [9] or whole cells treated with nuclear
poisons [10], can also be used as cytoplasm donors (Fig. 1). In cybrid
clones formed by the fusion of tumorigenic CHEF/16 hamster cells with
nontumorigenic CHEF/18 cytoplasts, the tumorigenicity was partially
suppressed, as assessed by the transformation rate in cell culture and by
the rate and extent of tumor formation in nude mice. Thus, this analysis
suggested that suppression of tumor-forming ability might be cytoplas-
mically transmitted [11]. These studies were performed with cell
populations that had undergone 20–30 doublings after the fusion,
therefore ruling out the role of nuclear gene products that would have
been diluted and thus reinforcing a possible role for mtDNA. The
suppression of tumorigenicity was also reported by using tumorigenic
rat thyroid cells and cytoplasts from epithelial cells derived from normal
rat thyroids [12]. Also, cybrids produced by fusing C2B2 tumorigenic
mouse mammary epithelial cells and cytoplasts from THOC nontumori-
genic BALB/c 3T3 ﬁbroblasts, after 7–13 postfusion doublings, showed a
reduction of the tumorigenic capacity in terms of tumor incidence and
latency when tested in newborn (less than 1 day old) BALB/c 3T3 mice
[13]. The cybrids derived from the fusion of highly tumorigenic mouse
teratocarcinoma lines (984 C1 10–15), which had lost the ability to
differentiate into skeletal muscle, and cytoplasts from nontumorigenic
mouse cells (AMT) did not retain the tumorigenicity of the original cell
line when evaluated in nudemice, andmost of the cybrids demonstrated
the ability to differentiate into skeletalmuscle. A factorwas present in the
nontumorigenic cell cytoplasmthatwasable to induce long-term(greater
than ayear in continuous culture) heritable suppressionof tumorigenicity
[14,15]. The fusion of normal rat hepatocyte cytoplasm to tumorigenic rat
hepatocyte whole cells resulted in suppression of the tumorigenicity in
only one of ﬁve cybrid clones analyzed when injected into newborn rat
pups that were isogenic with those from which the cell culture was
initiated. The cybrid clones produced tumors in 51% of the injected
animals compared to 92% of the animals injected with the tumorigenic
parent. Moreover, those animals that developed tumors from the cybrid
cells survived longer than those injected with cells from the tumorigenic
parent [15–17]. Tumorigenicitywas also suppressed in cybrids formed by
a fusionbetweencells fromhighly tumorigenicmousemelanomaB16and
cytoplasts from nontumorigenic rat myoblastic cells. At about 3 months
after the fusions, three cybrid cloneswere examined for tumorigenicity by
injection into nudemice. None of themproduced a tumorwithin 45 days
after the injection, althoughparental B16 cells produced tumors after only
7 days [18].
2.3. Recons
In the previous experiments, and others with cybrids that did not






Fig. 1. Cell models to study the inﬂuence of mtDNA mutations on cancer. The results of the fu
and white. Combined orange and white cytoplasm indicates nuclear gene products from both
of the original cells and mtDNA-encoded products from the other. Rho 0 cells contain mitotumoral cell was dilutedwith the one coming from the donor cytoplast,
so the contribution of each cytoplasm to the cell after several cell
generations is very difﬁcult to evaluate. Away to increase the cytoplasm
contribution from the donor nontumorigenic cell is through the
reconstituted cell (recons) approach. In this approach, most of the
cytoplasmof the receptor cell is removed, and a karyoplast is obtained. A
karyoplast is a nucleus surrounded by a thin cytoplasm layer (Fig. 1).
Thus, the fusion of normal rat hepatocyte cytoplasm to karyoplasts
obtained from tumorigenic hepatocytes resulted in suppression of
tumorigenicity in ﬁve of the six recons clones analyzed. Out of 68
animals injected with these reconstituted cells, only one tumor was
observed [15–17]. Tumorigenicity was also suppressed in reconstituted
cells formed by a fusion between karyoplasts from highly tumorigenic
mouse melanoma B16 cells and cytoplasts from nontumorigenic rat
myoblastic cells. At about3 monthsafter the fusions, three reconstituted
cell clones were examined for tumorigenicity by injection into nude
mice. None of themproduced a tumorwithin 45 days after the injection,
although parental B16 cells produced tumors after only 7 days [18].
The experiments performed with hamster cell cybrids [11] were
repeated using reconstituted cells. As in the cybrids, both tumor-
forming and -suppressing cloneswere obtained [24]. None of the recons
from tumorigenic NIH/3T3 BPDE 17 karyoplasts and nontumorigenic
NIH/3T3 cytoplasts was tumorigenic. In contrast, those with the same
karyoplast but cytoplast from NIH/3T3 BPDE 17 were tumorigenic [25].
Also, no recons from tumorigenic NIH/3T3 BPDE karyoplasts and
nontumorigenic B10mtJ cytoplasts were tumorigenic, but all the recons
from the same karyoplasts and tumorigenic B10mtJ cytoplasts were
tumorigenic [26].
2.4. Homoplasmic cybrids
A mix of mtDNA from the donor and receptor cells will be present
in cybrids and, in lesser extension, in recons. This condition is called
heteroplasmy. In contrast, a cell with only one type of mtDNA is called
homoplasmic. If cytoplasmic suppression is based upon mtDNA, then
the success of suppression would depend on relative replication rates
of both mtDNA and the impact of selective pressure [24]. Therefore, it
is important to remove the parental mtDNA to truly check the effect of
the donor mtDNA. This can be performed by using rho0 cells (cells
without mtDNA) [27] or by pretreating cells with the toxic
mitochondrial dye, rhodamine 6G [28] (Fig. 1). It has been shown
that PC3 prostate cancer cells were able to produce big tumors in nude
mice after 4 weeks [29]. However, cybrids produced by treating PC3
cells with rhodamine 6G and fusing them to cytoplasm from a cell line
without mtDNA mutations barely grew in nude mice after 4 months
[30]. Interestingly, the original mtDNA of PC3 cells harbored two
mutations. The ﬁrst, m.11120TNC/p.MT-ND4:F121L, has not been
described in more than 3500 human mtDNAs [31], and it has a lowKaryoplast Cytoplast ρo Cell Cytoplast
+ +
Recons Cybrids (ρo)
sion after several cell generations are represented. Different origins are coded in orange
origins. Striped mitochondria mirror a mixed origin with nuclear gene products of one
chondria but do not have mtDNA.
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However, the second one, m.13802CNT/p.MT-ND5:T489M, could be
functionally relevant. It was previously found in an individual, but the
age, sex, or health status was not reported. The affected position has a
moderate conservation index, and it is possible that removal of this
mutation reduced the tumorigenic potential of the PC3 cells [30].
3. Mitochondrial DNA enhancement of tumor formation
Most of the proteins and RNAs in the cybrid cells are nucleus-
encoded products. This means that most of the donor cytoplasm
proteins and RNAs will be diluted after several culture passages after
the cybrid construction. Only 37 RNAs and proteins in the cybrid cells
do not have this origin. These are mtDNA-encoded products, and they
will remain in the mitochondria cell generation after cell generation.
This fact suggests that the donor mtDNA was responsible for the
suppression of the tumorigenicity in the previous experiments. If the
new mtDNA suppresses the tumorigenicity, the substituted one
should favor the tumoral process.
In one study, portions of an immortalized and cloned rat liver-
derived epithelial cell culture were sequentially frozen. Nontrans-
formed early and transformed late passage cells were retrieved.
Cybrids derived from the fusion of normal whole cells to cytoplasts
from malignantly transformed cells produced tumors in 17% of the
newborn rat pups injected. Recons derived from the fusion of
karyoplasts of normal cells with cytoplasts from malignant cells
produced tumors in 97% of the animals injected [32]. New mutations
that accumulated in the mtDNA of the transformed late passage cells
could explain the previous results. MtDNA can mutate in cultured
cells. Thus, HeLa cell sublines, isolated and maintained in culture for
decades, have accumulated mtDNA mutations. One of these sublines
harbors a premature chain termination codon m.12533GNA/p.MT-
ND5:W66TER. Although this mutation was not characterized, it likely
has a dramatic phenotypic effect on the OXPHOS function [33].
Cybrids can also accumulate mtDNA mutations during culture. For
example, the AL4.3 line showed three new mtDNA mutations
(m.1843TNC, m.1940ANG, and m. 2623ANG, all of them in the MT-
RNR2 gene) and a negative bioenergetic phenotype [34].
Otto Warburg proposed that tumor cells have a heritable
respiration defect. Surprisingly, before the discovery of the mtDNA
in animal cells [35], Warburg wrote “…we understand why the
respiration connected with the grana remains damaged when it has
once been damaged; it is for the same reason that properties linked
with genes remain damaged when the genes have been damaged”
[36]. Once a mitochondrion was damaged, it remained so, transmit-
ting its defect to progeny (presumably mitochondria), just as would
occur, he asserted, in the case of a damaged nuclear gene [37].
Soon after its discovery, mtDNA began to be analyzed in tumoral
cells [38]. Since then, many mtDNA mutations have been found in
different tumors [39], but their impact on tumorigenicity has not been
well established. However, the nature of some of these mutations
pointed to a phenotypic effect on mitochondrial respiration. For
example, the ﬁrst tumor likely to be associated with a mtDNA
mutation with phenotypic consequences was reported in 1983 [40].
This was the deletion of a C within a tract of three C's (nucleotide
positions 5550–5552, human numbering) in the anticodon stem of
the MT-TW gene in a rat tumor. Only two insertions/deletions have
been reported in this stem in human mt-tRNAs: a deletion of one of
three T-A nucleotide pairs in the MT-TL1 gene [41] and a single T
insertion at nucleotide position 5537 in theMT-TW [42,43]. Bothwere
associated with a pathological condition, a mitochondrial disease.
Another clue that a mtDNA mutation in cancer cells could be
functionally signiﬁcant came from the report of a renal adenocarci-
noma in which 50% of the mtDNAs contained a 264-nt in-frame
deletion in the MT-ND1 gene, resulting in a truncated mRNA [44]. It
should be considered that mtDNA deletions are a relatively frequentcause of mitochondrial disease [45]. In the case of mtDNA mutations
causing stop codons, they will truncate the protein and will probably
have a phenotypic effect. The ﬁrst mtDNA stop codon mutation
associated with cancer was found in a colorectal tumor. This was a
m.6264GNA/p.MT-CO1:G121TERmutation [46]. It has been found that
similar changes, such as the m.6930GNA/p.MT-CO1:G343TER muta-
tion, are associated with mitochondrial disorders [47].
Transmitochondrial cell lines (cybrids) canbeused to check theeffect
of cancer-associated mtDNA mutations [48]. For some tumor mtDNA
mutations, a biochemical and molecular analysis has been carried out.
Osteosarcoma 143B cybrids harboring two mtDNA mutations from the
thyroid oncocytic cell lineXTC.UC1,m.3571Ci that provokes a frameshift
and a stop codon at p.MT-ND1:G101TER (N92.6% mutant) and
m.15557GNA/p.MT-CYB:E271K (N27% mutant), showed decreased
viability and ATP levels when grown in galactose medium, which forces
mammalian cells to rely on mitochondrial OXPHOS [49]. Moreover, a
homoplasmic cybrid clone for them.3571Cimutation grewmore slowly
in galactose medium and was defective in complex I assembly and ATP
synthesis when compared with another cybrid clone that was 80%
mutant. This homoplasmic cybrid also showed a α-ketoglutarate/
succinate ratio that was signiﬁcantly higher [50]. Osteosarcoma 143B
cybrids were also built withmitochondria from the VACO 425 colorectal
cancer cell line [46]. In addition to the m.6264GNA/p.MT-CO1:G121TER
mutation, this mtDNA contained an insertion of a single A nucleotide at
position m.12418 (m.12418Ai) that causes a reading frame shift at
K28, thereby producing a truncated p.MT-ND5 protein. No p.MT-ND5
or p.MT-CO1 was detected in these cybrids. In consequence, they
showed extremely low endogenous respiration and markedly reduced
complex I+III and IV activities [51]. Other osteosarcoma 143B cybrids,
harboring the m.12418Ai mutation but without the m.6264GNA
mutation, had less oxygen consumption, less ATP synthesis, and grew
more slowly in galactose medium. They also produced more extracel-
lular lactate, more mitochondrial superoxide and overexpressed some
antioxidant enzymes [52]. Moreover, osteosarcoma 143B cybrids
harboring mtDNA mutations (m.7458GNA/MT-TS1 and m.15894GNA/
MT-TT) from two breast cancer cell lines (MDA-MB-231 andMDA-MB-
436) showed lower levels of the two affected tRNAs, lower respiratory
complex activities, a reduced oxygen consumption, decreased ATP
synthesis, and,ﬁnally a signiﬁcantly reduced cell viabilitywhengrown in
galactose medium [53].
However, an OXPHOS defect due to these mutations does not mean
that the mutations affect the tumorigenicity. To check this important
point, several studies usedmice to analyze the tumorigenicity of cybrids
with different mtDNA mutations. Thus, nude mice were injected with
cybrids derived from a rhodamine 6G-treated PC3 prostate cancer cell
line and cytoplasts harboring am.8993TNG/p.MT-ATP6:L156Rmutation
or isogenic cybrids without this mutation. Patients with this mutation
suffered a mitochondrial disease [54], and osteosarcoma 143B cybrids
with the mutation showed an OXPHOS defect [55]. The mutant PC3
cybrids were found to generate tumors that were seven times larger
than the wild-type cybrids. The mutant tumors also generated
signiﬁcantly more ROS. Therefore, these results showed that mtDNA
mutations could play an important role in cancer [30,56]. In the same
year, HeLa cybrids with or without the pathologic m.8993TNG and
m.9176TNC/p.MT-ATP6:L217P [57] mutations were injected into nude
mice. These mutations conferred an advantage in the early stage of
tumor growth. Because apoptosis occurred less frequently in mutant
cybrids, themtDNAmutation seemed to promote tumors by preventing
apoptosis [58]. A higher metastatic potential of cells with mtDNA
mutations was suggested after the observation that osteosarcoma
cybrids harboring the m.3243ANG/MT-TL1 mutation were more
invasive in a matrigel invasion assay than those built with a wild-type
mtDNA [59]. This issue was conﬁrmed in another experiment in which
mitochondria from poorly and highlymetastatic mouse tumor cell lines
were interchanged. The highly metastatic cell line contained the
m.13997GNA/p.MT-ND6:P25L andm.13885Ci/p.MT-ND6 (this insertion
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respiratory complex I activity associated with the overproduction of
ROS. By using metastasis assays in mice, it was found that the recipient
tumor cells acquired themetastatic potential of the transferred mtDNA.
Thus, these results indicated thatmtDNAmutations could contribute to
tumor progression by enhancing the metastatic potential of these cells
[60]. The ﬁrst evidence that amtDNAmutation found in a human tumor
was able to affect tumorigenicity was recently obtained. Cybrids
harboring the heteroplasmic m.12418Ai mutation (there is a tract of
8 As beginning at 12418, therefore this mutation should be called
m.12425Ai), the same mutation found in a colorectal tumor [46],
produced tumors that grew faster and were larger in volume when
injected into nude mice that those from wild type cybrids [52].
4. MtDNA mutations and tumorigenicity
Cell proliferation is controlled by an interaction with other cells
and the extracellular matrix and by the levels of growth factors.
Therefore, the earliest steps in carcinogenesis require nuclear genetic
alterations to surmount these tissue constraints. These requirements
probably explain why the cytoplasm from tumoral cells is unable to
provoke tumorigenicity in normal cells. As proliferation pushes cells
further away from their blood supply and oxygen concentrations
decrease, premalignant lesions will face hypoxic regions near the
oxygen diffusion limit. Near-zero partial pressures of oxygen are
observed at short distances from a blood vessel, where cells are
exposed to an unstable environment due to hypoxia–reoxygenation
cycles. In this hypoxic microenvironment, selection forces will favor
phenotypes that adapt to anaerobic metabolism [61]. When oxygen
levels are very low, the electron carriers of the mitochondrial
respiratory chain will remain more reduced [62], more mitochondrial
ROS will be generated and hypoxia-inducible factors (HIFs) will be
activated [63]. HIF1α acts a transcriptional factor triggering the
expression of many genes, among them, those for glycolytic enzymes.
In this way, tumoral cells enhance their glycolytic metabolism and
their survival in this hypoxic environment. However, cells derived
from tumors typically maintain their metabolic phenotypes in culture
under normoxic conditions, indicating that aerobic glycolysis is
constitutively upregulated through stable genetic or epigenetic
changes.
In hypoxia–reoxygenation cycles, higher ROS amounts can be
produced, and these are mutagenic compounds. Hypoxic conditions
are sufﬁcient to generate mutations in nuclear [64] andmitochondrial
[65] genes. Thus, the metabolic phenotype, as another proliferation
barrier [1], might be acquired by different nDNA and mtDNA
mutations. Therefore, despite the fact that mtDNA mutations are not
necessary for some tumors, they might contribute to many others. In
fact, mtDNA accumulates mutations much faster than nDNA. MtDNA
is located in the mitochondrial matrix and is bound to the inner
membrane where the electron transport chain (ETC), the main source
of ROS in the cell, is embedded. Moreover, the mutational process
induced by ROS is facilitated because repair systems for mtDNA are
not as abundant as those for nDNA [66]. Interestingly, DNA repair
pathways may be compromised in cells exposed to hypoxic condi-
tions [67]. Together, these facts can explain the high frequency of
mtDNA mutations found in cancer cells [68].
A high frequency of homoplasmic mtDNA mutations has been
reported in human tumors. It has been estimated that only approxi-
mately 70 cell generations are required for a mutation to become
homoplasmic by chance [69]. However, in the earliest steps of
carcinogenesis, most cells die by necrosis when exposed to hypoxia
[61]. Therefore, they do not have an unlimited possibility of prolifer-
ation. After a very small number of cell divisions, they will face this
hypoxic environment and be removed. However, a mtDNA mutation
that increases ROS productionwill provide selective advantages. Higher
percentages of themutationwill offer higher survival possibilities. Thus,it is possible thatmanymtDNAmutationswill appear andbeenriched in
this hypermutagenic environment because they contribute to the
tumoral phenotype, and not just by chance.
In addition to survival in a particular microenvironment, other
tumor-related phenotypes can be associated with mtDNA mutations.
Thus, OXPHOS-deﬁcient cybrids due to a mtDNA deletion upregulate
and downregulate the expression of matrix metalloproteinase 1
(MMP1) and its natural inhibitors (tissue inhibitors of the MMP
family, TMP1 and TMP2), respectively. Moreover, HIF1α stimulates
the production of angiogenic factors, such as VEGF, and this promotes
increased vascularity and metastases. These results suggest that
OXPHOS defects also participate in tumor progression by modulating
extracellular matrix remodeling and angiogenic processes [59].
5. Mitochondrial DNA inherited susceptibility to cancer phenotypes
Mutations in the p.MT-CO1 subunit have been found in many
different tumors, although population polymorphisms and patholog-
ical mutations in this gene are relatively uncommon. Thus, MT-CO1
mutations were present in 11% of 180 prostate cancer specimens from
European American patients, 0% of 46 European American noncancer
controls and 6.5% of a population of 898 samples from European
ancestors without information about their sex, age, and health status.
Therefore, MT-CO1 mutations are signiﬁcantly increased in prostate
cancer samples over the noncancer controls and the general
population. Moreover, the interspeciﬁc conservation of the altered
p.MT-CO1 amino acids in prostate cancer was signiﬁcantly higher
than that in the general population. These results suggest that p.MT-
CO1 mutations must be functionally signiﬁcant. Due to most of the
MT-CO1 mutations being homoplasmic in different tissues of the
patients, they must have arisen in the female germ line. Therefore,
inherited mtDNA mutations could be a risk factor for cancer [30].
Several types of cancers show geographic or ethnic clustering. As an
example, the incidence of prostate cancer ismuch higher amongmen of
African descent compared to Europeans. In addition to environmental
factors that likely contribute to the regional differences in prevalence,
genetic susceptibility could be another risk factor. Thus, different alleles
of nuclear genes have been proposed to explain some of these
geographic or ethnic differences [70,71]. In contrast to the nuclear
genome, mtDNA shows considerable geographic and ethnic diversity
[72]. MtDNA is inherited by maternal lineage. When a mutation in the
mtDNA appears and survives in the population, a newmaternal lineage
is formed. With time, new mutations will create new branches,
producing a mtDNA phylogenetic tree. The groups of phylogenetically
related mtDNA genotypes are known as mtDNA haplogroups. Phylo-
geographic studies of human mtDNAs have revealed a remarkable
correlation between mtDNA lineages and the geographic origins of
indigenous populations. The humanmtDNA tree is rooted in Africa, and
it has speciﬁc branches radiating into different geographical regions
[72]. African mtDNAs are the most diverse and ancient and fall into
several major haplogroups known as L lineages. In northeastern Africa,
two main mtDNA lineages, M and N, arose and were successful in
leaving sub-SaharanAfrica and radiating into Eurasia to give rise to all of
the Eurasian mtDNA haplogroups (Fig. 2). Therefore, this geographical
mtDNA variability could contribute to the geographical clustering of
some cancers.
Carcinogenesis is a multistep process often described as somatic
evolution. As we have previously mentioned, somatic evolution of
cancer cells can be viewed as a sequence of phenotypical adaptations
to distinct microenvironmental barriers. Models of carcinogenesis are
typically based on the Darwinian principle that evolution requires
genetic changes that generate new phenotypes [1]. Interestingly,
many tumor-speciﬁc somatic mtDNAmutations have also been found
as haplogroup-deﬁning population genetic variants. These mutations
may facilitate the tumor survival under new environments with
altered or reduced energetic substrates, reduced oxygen tension,
L M N
EuropeAfrica India
Fig. 2. Mitochondrial DNA phylogenetic tree. The major mtDNA genetic lineages are
represented along with their geographic distribution according to the studies discussed in
the text. Mutations affecting the m.10398 position are marked (black circle is m.10398G
allele and white circle is m.10398A allele).
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Because humans in their expansion across the planet also faced
similar environmental challenges, the same mtDNA mutations might
be adaptive in both tumors and people [39]. Therefore, it would be
possible that the mitochondrial haplogroup behaves as a susceptibil-
ity factor for carcinogenesis.
A transition in the m.10398 position has been found at 12 internal
nodes of a mtDNA phylogenetic tree including more than 3500
sequences [31] (Fig. 2). The m.10398G (p.MT-ND3:A114) allele is
probably from the most recent common ancestor of humans
(mitochondrial Eve), and it is prevalent in individuals of African
heritage. The m.10398A allele (p.MT-ND3:T114), along with other
polymorphisms, deﬁnes the mtDNA N macrolineage. This allele is
prevalent in individuals of European heritage. Positive selection has
been invoked to explain the high number of times that an m.10398
mutation has occurred in the human phylogeny and the fact that the
human-derived allele predominates in the mammalian consensus
sequence [73]. In a study including 1259 African-American women
(654 patients and 605 controls), it was found that the A allele was
associated with a signiﬁcantly increased risk of invasive breast cancer
[74]. This allele was not found to be associated with breast cancer in
another study of African-American women that included 1456
patients and 978 controls [75], but it was found to be overrepresented
in African-American men with organ-conﬁned prostate cancer [76].
This allele was also signiﬁcantly associated with an increased risk for
sporadic breast carcinoma in India. In this population, the m.10398A
along with the m.10400C polymorphisms deﬁne macrohaplogroup N.
The m.10398G and m.10400T polymorphisms deﬁne macroha-
plogroup M. Interestingly, there is an apparent worldwide correlation
between the increased incidence rate of breast cancer and mtDNA
macrohaplogroup N distribution. In India, those states with the
highest prevalence of major macrohaplogroup N correlated with the
highest breast cancer incidence rate. A comparison between sporadic
breast cancer cases and controls with mtDNA genetic backgrounds M
and N showed that the macrohaplogroup N was overrepresented in
the cases. Moreover, in another cancer type, the squamous cell
carcinoma of esophagus, macrohaplogroup N was also overrepre-
sented [77]. However, in another study from India including 308 oral
cancer patients and 383 controls, the Mmacrolineage was found to be
associated with cancer [78]. By using cybrids, mitochondrial func-
tional differences were found betweenmacrohaplogroups N and non-
N. It was shown that cybrids from themacrohaplogroup N had a lower
mitochondrial matrix pH and higher mitochondrial calcium levels
when compared with that of the macrohaplogroup non-N [79].
Curiously, in studies of individuals with European heritage, results
are different. Thus, it was found that the m.10398G allele wasassociated with breast cancer in a study including 156 European-
American breast cancer patients with a family history of breast cancer
and 260 controls [80]. In another study from Poland, the m.10398G
allele was present in 23% of 44 sporadic breast cancer patients but
only in 3% of 100 controls [81]. However, the m.10398G allele was not
found to be associated with breast cancer in two other studies (1561
breast cancer patients and 2209 controls; 678 breast cancer patients
and 669 controls) [82].
These contradictory results from epidemiological studies are
difﬁcult to interpret. For example, due to the absence of recombina-
tion in human mtDNA, it is possible that the m.10398G mutation was
in linkage disequilibrium with a more important causative polymor-
phism. A highly signiﬁcant interaction was identiﬁed between this
variant and the m.4216C or m.12308G mutations in patients suffering
from breast cancer [83]. The ﬁrst combination deﬁnes haplogroup J,
and the second one deﬁnes haplogroup Uk1. Uk1, along with J1c, one
of most frequent subhaplogroups J in Europe, share another mtDNA
polymorphism with a potential phenotypic effect, m.14798C [84].
Different combinations of diverse genetic and environmental factors
may be involved in cancer. If mtDNA population polymorphisms are
involved in the tumorigenicity process, their contributions can be
important, although they will not be dramatic. It is expected that they
would have small effects on OXPHOS function, and these effects
would be highly dependent on the “context” in which the genetic
variant is acting. To solve this issue, epidemiological studies will not
be very useful and other approaches are required. Cybrids can, again,
help to elucidate the role of mtDNA population polymorphisms in the
susceptibility to cancer. A cybrid with the m.10398A polymorphism
showed a slower proliferation rate and altered progression through
the cell cycle, as well as increased complex I activity and levels of
reactive oxygen species and depolarized mitochondria, compared to
another cybrid with the m.10398G allele. It also showed resistance to
apoptosis triggered by etoposide, increased Akt phosphorylation in
the S473 residue, and an increased number of anchorage-independent
colonies in vitro and metastases in mice [85].
Another example that shows theutilityof the cybrid approachcomes
from the CFPAC-1 and CAPAN-2 human pancreatic cancer cell lines.
These contain never before described nonsynonymous mutations,
m.8696TNC/p.MT-ATP6:M57T and m.10176GNA/p.MT-ND3:G40S, re-
spectively [86]. The phenotypic effects of thesemtDNA genotypes were
not very dramatic. Cybrids prepared using mitochondria derived from
these cells did not show signiﬁcant differences in mitochondrial inner
membrane potential and oxygen consumption, although they tended to
be different, and they grew slower than wild-type cybrids [87].
Interestingly, one of these cell lines (CAPAN-2) also contained the
m.6267GNA/p.MT-CO1:A122T mutation. This mutation was also found
in 1 of 260 patients with prostate cancer [30], 1 of 63 patients with
breast cancer, 1 of 64 patients with colon cancer, and 2 of 13 cancer cell
lines [88]. Altogether, it was found in 6 out of 415 samples frompatients
with cancer. Biochemical analysis of cybrids with this mutation
indicated that growth in galactose medium, respiration, and complex
IV activity were impaired [88]. This mutation has also been found ﬁve
times in more than 3500 “control” individuals, whose age and health
status were unknown [31]. Interestingly, two of them belonged to the
same mitochondrial haplogroup, M38 [89]. The complete sequences of
these two individuals allowed characterization of this haplogroup-
deﬁningmutation as an ancient one, being present in the population for
thousands of years. Since the appearance of this mutation, at least ﬁve
and seven other mutations accumulated in the mtDNA lineages that
produced themtDNA genotypes harbored by these two individuals. The
high frequency of thismutation in cancer samples and its rareness in the
normal population, along with its effect on the OXPHOS function of
transmitochondrial cell lines, raise the possibility that this transition
might inﬂuence the tumoral phenotype. Conﬁrming this suggestion,
cybrids harboring mitochondria from the CAPAN-2 human pancreatic
cancer cell line and from healthy individuals were transplanted into
648 M.P. Bayona-Bafaluy et al. / Biochimica et Biophysica Acta 1807 (2011) 643–649nude mice to generate tumors. Tumors derived from cybrids with
mtDNA from cancer lines were more resistant than those with mtDNA
from healthy individuals in suppressing tumor growth and inducing
massive apoptosis when anticancer drugs were administered [87].
Mutations in mtDNA can be responsible for the anticancer drug
tolerance of tumoral cells, but mtDNA population polymorphisms can
also affect the tumoral phenotype in a different way. Thus, the
mitochondrial genetic background may affect the appearance of side
effects after anticancer therapy. Cisplatin is a highly effective
chemotherapeutic agent, but its use is limited by its nephrotoxicity,
neurotoxicity, and ototoxicity. It was recently shown that 5 of 20
patients with hearing impairment under therapeutic doses of cisplatin
belonged to the mtDNA haplogroup J, but only 1 of 19 patients
without hearing impairment belonged to this haplogroup [90].
6. Conclusions
The tumoral microenvironment favors the appearance of mtDNA
mutations. Some of these mutations can affect the cancer phenotype by
altering tumor metabolism. The OXPHOS system is important for
adapting to the environment. In fact, external signals, such as nutrients
and oxygen, interact at the OXPHOS level and modify the levels of
secondmessengers, such as ATP, ROS, and Ca2+, or the cell red–ox state,
then triggering intracellular retrograde responses important for
surmounting the microenvironmental barriers to proliferation.
Along human evolution, mtDNA has accumulatedmutations. Many
of these surely did not have any phenotypic effect, but some of them
probably assisted individual survival by modifying the OXPHOS
balances. Thus, individuals from diverse haplogroups would have
small differences in their metabolism and, therefore, distinct
susceptibilities to cancer. Because cancer is a multifactorial disorder,
small metabolic differences due to mtDNA SNPs can be difﬁcult to
analyze in epidemiological studies, and other approaches are
required. As we have seen in this review, cybrids and nude mice can
be interesting tools to study the inﬂuence of population polymorph-
isms and mtDNA-inherited susceptibility to cancer.
Acknowledgments
This project was supported by grants from the Instituto de Salud
Carlos III-FIS (PI07-0045 and PI08-0264) and the Diputación General
de Aragón (Grupos consolidados B33 and PI083/08). CIBERER is an
initiative of the ISCIII.
References
[1] R.A. Gatenby, R.J. Gillies, A microenvironmental model of carcinogenesis, Nat. Rev.
Cancer 8 (2008) 56–61.
[2] N.G. Copeland, N.A. Jenkins, Deciphering the genetic landscape of cancer—from
genes to pathways, Trends Genet. 25 (2009) 455–462.
[3] R.A. Beckman, L.A. Loeb, Genetic instability in cancer: theory and experiment,
Semin. Cancer Biol. 15 (2005) 423–435.
[4] W.D. Foulkes, Inherited susceptibility to common cancers, N Engl J. Med. 359
(2008) 2143–2153.
[5] J. Jonasson, H. Harris, The analysis of malignancy by cell fusion: VIII. Evidence for
the intervention of an extra-chromosomal element, J. Cell Sci. 24 (1977) 255–263.
[6] H.G. Coon, The genetics of the mitochondrial DNA of mammalian somatic cells,
their hybrids and cybrids, Natl Cancer Inst. Monogr. (1978) 45–55.
[7] C.L. Bunn, D.C. Wallace, J.M. Eisenstadt, Cytoplasmic inheritance of chloramphen-
icol resistance in mouse tissue culture cells, Proc. Natl Acad. Sci. USA 71 (1974)
1681–1685.
[8] A. Chomyn, S.T. Lai, R. Shakeley, N. Bresolin, G. Scarlato, G. Attardi, Platelet-
mediated transformation of mtDNA-less human cells: analysis of phenotypic
variability among clones from normal individuals—and complementation
behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red
ﬁbers, Am. J. Hum. Genet. 54 (1994) 966–974.
[9] K. Inoue, S. Ito, D. Takai, A. Soejima, H. Shisa, J.B. LePecq, E. Segal-Bendirdjian, Y.
Kagawa, J.I. Hayashi, Isolation of mitochondrial DNA-less mouse cell lines and
their application for trapping mouse synaptosomal mitochondrial DNA with
deletion mutations, J. Biol. Chem. 272 (1997) 15510–15515.[10] M.P. Bayona-Bafaluy, G. Manfredi, C.T. Moraes, A chemical enucleation method for
the transfer of mitochondrial DNA to rho(o) cells, Nucleic Acids Res. 31 (2003)
e98.
[11] A.N. Howell, R. Sager, Tumorigenicity and its suppression in cybrids of mouse and
Chinese hamster cell lines, Proc. Natl Acad. Sci. USA 75 (1978) 2358–2362.
[12] H.G. Coon, J. Cell Biol. 83 (1979) 449a.
[13] L. Giguere, R. Morais, On suppression of tumorigenicity in hybrid and cybrid
mouse cells, Somatic Cell Genet 7 (1981) 457–471.
[14] J.W. Shay, G. Lorkowski, M.A. Clark, Suppression of tumorigenicity in cybrids,
J. Supramol. Struct. Cell. Biochem. 16 (1981) 75–82.
[15] J.W. Shay, Cytoplasmic modiﬁcation of nuclear gene expression, Mol. Cell.
Biochem. 57 (1983) 17–26.
[16] B.A. Israel, W.I. Schaeffer, In Vitro 18 (1982) 284.
[17] B.A. Israel, W.I. Schaeffer, Cytoplasmic suppression of malignancy, In Vitro Cell.
Dev. Biol. 23 (1987) 627–632.
[18] M. Koura, H. Isaka, M.C. Yoshida, M. Tosu, T. Sekiguchi, Suppression of
tumorigenicity in interspeciﬁc reconstituted cells and cybrids, Gann 73 (1982)
574–580.
[19] M.L. Ziegler, Phenotypic expression of malignancy in hybrid and cybrid mouse
cells, Somatic Cell Genet 4 (1978) 477–489.
[20] M.W. McBurney, B. Strutt, Fusion of embryonal carcinoma cells to ﬁbroblast cells,
cytoplasts, and karyoplasts. Developmental properties of viable fusion products,
Exp. Cell Res. 124 (1979) 171–180.
[21] R. Halaban, G. Moellmann, E. Godawska, J.M. Eisenstadt, Pigmentation and
tumorigenicity of reconstituted, cybrid and hybrid mouse cells, Exp. Cell Res. 130
(1980) 427–435.
[22] J. Hayashi, Y. Tagashira, T. Watanabe, M.C. Yoshida, Effect of mitochondrial DNA
transmitted cytoplasmically from nontumorigenic to tumorigenic rat cells on the
phenotypic expression of tumorigenicity, Cancer Res. 44 (1984) 3957–3960.
[23] J. Hayashi, H. Werbin, J.W. Shay, Effects of normal human ﬁbroblast mitochondrial
DNA on segregation of HeLaTG mitochondrial DNA and on tumorigenicity of
HeLaTG cells, Cancer Res. 46 (1986) 4001–4006.
[24] R. Sager, Genetic suppression of tumor formation, Adv. Cancer Res. 44 (1985)
43–68.
[25] J.W. Shay, H. Werbin, Cytoplasmic suppression of tumorigenicity in reconstructed
mouse cells, Cancer Res. 48 (1988) 830–833.
[26] J.W. Shay, Y.N. Liu, H. Werbin, Cytoplasmic suppression of tumor progression in
reconstituted cells, Somat. Cell Mol. Genet. 14 (1988) 345–350.
[27] M.P. King, G. Attardi, Human cells lacking mtDNA: repopulation with exogenous
mitochondria by complementation, Science 246 (1989) 500–503.
[28] I. Trounce, D.C. Wallace, Production of transmitochondrial mouse cell lines by
cybrid rescue of rhodamine-6G pre-treated L-cells, Somat. Cell Mol. Genet. 22
(1996) 81–85.
[29] G. Zhang, H. Zhang, Q. Wang, P. Lal, A.M. Carroll, M. de la Llera-Moya, X. Xu, M.I.
Greene, Suppression of human prostate tumor growth by a unique prostate-
speciﬁc monoclonal antibody F77 targeting a glycolipid marker, Proc. Natl Acad.
Sci. USA 107 (2010) 732–737.
[30] J.A. Petros, A.K. Baumann, E. Ruiz-Pesini, M.B. Amin, C.Q. Sun, J. Hall, S. Lim, M.M.
Issa, W.D. Flanders, S.H. Hosseini, F.F. Marshall, D.C. Wallace, mtDNA mutations
increase tumorigenicity in prostate cancer, Proc. Natl Acad. Sci. USA 102 (2005)
719–724.
[31] E. Ruiz-Pesini, M.T. Lott, V. Procaccio, J.C. Poole, M.C. Brandon, D. Mishmar, C. Yi, J.
Kreuziger, P. Baldi, D.C. Wallace, An enhanced MITOMAP with a global mtDNA
mutational phylogeny, Nucleic Acids Res. 35 (2007) D823–D828.
[32] B.A. Israel, W.I. Schaeffer, Cytoplasmic mediation of malignancy, In Vitro Cell. Dev.
Biol. 24 (1988) 487–490.
[33] C. Herrnstadt, G. Preston, R. Andrews, P. Chinnery, R.N. Lightowlers, D.M. Turnbull,
I. Kubacka, N. Howell, A high frequency of mtDNA polymorphisms in HeLa cell
sublines, Mutat. Res. 501 (2002) 19–28.
[34] P. Seibel, C. Di Nunno, C. Kukat, I. Schafer, R. Del Bo, A. Bordoni, G.P. Comi, A. Schon,
F. Capuano, D. Latorre, G. Villani, Cosegregation of novel mitochondrial 16 S rRNA
gene mutations with the age-associated T414G variant in human cybrids, Nucleic
Acids Res. 36 (2008) 5872–5881.
[35] S. Nass, M.M. Nass, Intramitochondrial ﬁbers with DNA characteristics: II.
Enzymatic and other hydrolytic treatments, J. Cell Biol. 19 (1963) 613–629.
[36] O. Warburg, On the origin of cancer cells, Science 123 (1956) 309–314.
[37] H.D. Hoberman, Is there a role for mitochondrial genes in carcinogenesis? Cancer
Res. 35 (1975) 3332–3335.
[38] S. Nass, M.M. Nass, Intramitochondrial ﬁbers with deoxyribonucleic acid
characteristics: observations of Ehrlich ascites tumor cells, J. Natl Cancer Inst.
33 (1964) 777–798.
[39] M. Brandon, P. Baldi, D.C. Wallace, Mitochondrial mutations in cancer, Oncogene
25 (2006) 4647–4662.
[40] M. Taira, E. Yoshida, M. Kobayashi, K. Yaginuma, K. Koike, Tumor-associated
mutations of rat mitochondrial transfer RNA genes, Nucleic Acids Res. 11 (1983)
1635–1643.
[41] J.M. Shoffner, M.G. Bialer, S.G. Pavlakis, M. Lott, A. Kaufman, J. Dixon, S. Teichberg,
D.C. Wallace, Mitochondrial encephalomyopathy associated with a single
nucleotide pair deletion in the mitochondrial tRNALeu(UUR) gene, Neurology
45 (1995) 286–292.
[42] F.M. Santorelli, K. Tanji, M. Sano, S. Shanske, M. El-Shahawi, P. Kranz-Eble, S.
DiMauro, D.C. De Vivo, Maternally inherited encephalopathy associated with a
single-base insertion in the mitochondrial tRNATrp gene, Ann. Neurol. 42 (1997)
256–260.
[43] M. Tulinius, A.R. Moslemi, N. Darin, B. Westerberg, L.M. Wiklund, E. Holme, A.
Oldfors, Leigh syndrome with cytochrome-c oxidase deﬁciency and a single T
649M.P. Bayona-Bafaluy et al. / Biochimica et Biophysica Acta 1807 (2011) 643–649insertion nt 5537 in the mitochondrial tRNATrp gene, Neuropediatrics 34 (2003)
87–91.
[44] T.M. Horton, J.A. Petros, A. Heddi, J. Shoffner, A.E. Kaufman, S.D. Graham Jr., T.
Gramlich, D.C. Wallace, Novel mitochondrial DNA deletion found in a renal cell
carcinoma, Genes Chromosom. Cancer 15 (1996) 95–101.
[45] I.J. Holt, A.E. Harding, J.A. Morgan-Hughes, Deletions of muscle mitochondrial DNA
in patients with mitochondrial myopathies, Nature 331 (1988) 717–719.
[46] K. Polyak, Y. Li, H. Zhu, C. Lengauer, J.K. Willson, S.D. Markowitz, M.A. Trush, K.W.
Kinzler, B. Vogelstein, Somatic mutations of the mitochondrial genome in human
colorectal tumours, Nat. Genet. 20 (1998) 291–293.
[47] C. Bruno, A. Martinuzzi, Y. Tang, A.L. Andreu, F. Pallotti, E. Bonilla, S. Shanske, J. Fu,
C.M. Sue, C. Angelini, S. DiMauro, G. Manfredi, A stop-codon mutation in the
human mtDNA cytochrome c oxidase I gene disrupts the functional structure of
complex IV, Am. J. Hum. Genet. 65 (1999) 611–620.
[48] S. Ohta, Contribution of somatic mutations in the mitochondrial genome to the
development of cancer and tolerance against anticancer drugs, Oncogene 25 (2006)
4768–4776.
[49] E. Bonora, A.M. Porcelli, G. Gasparre, A. Biondi,A.Ghelli, V. Carelli, A. Baracca, G. Tallini,
A. Martinuzzi, G. Lenaz, M. Rugolo, G. Romeo, Defective oxidative phosphorylation in
thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA
mutations affecting complexes I and III, Cancer Res. 66 (2006) 6087–6096.
[50] A.M. Porcelli, A. Ghelli, C. Ceccarelli, M. Lang, G. Cenacchi, M. Capristo, L.F. Pennisi,
I. Morra, E. Ciccarelli, A. Melcarne, A. Bartoletti-Stella, N. Salﬁ, G. Tallini, A.
Martinuzzi, V. Carelli, M. Attimonelli, M. Rugolo, G. Romeo, G. Gasparre, The
genetic andmetabolic signature of oncocytic transformation implicates HIF1alpha
destabilization, Hum. Mol. Genet. 19 (2010) 1019–1032.
[51] S. Srivastava, J.N. Barrett, C.T. Moraes, PGC-1alpha/beta upregulation is associated
with improved oxidative phosphorylation in cells harboring nonsense mtDNA
mutations, Hum. Mol. Genet. 16 (2007) 993–1005.
[52] J.S. Park, L.K. Sharma, H. Li, R. Xiang, D. Holstein, J. Wu, J. Lechleiter, S.L. Naylor, J.J.
Deng, J. Lu, Y. Bai, A heteroplasmic, not homoplasmic, mitochondrial DNA
mutation promotes tumorigenesis via alteration in reactive oxygen species
generation and apoptosis, Hum. Mol. Genet. 18 (2009) 1578–1589.
[53] Y. Ma, R.K. Bai, R. Trieu, L.J. Wong, Mitochondrial dysfunction in human breast cancer
cells and their transmitochondrial cybrids, Biochim. Biophys. Acta 1797 (2010) 29–37.
[54] I.J. Holt, A.E. Harding, R.K. Petty, J.A. Morgan-Hughes, A newmitochondrial disease
associated with mitochondrial DNA heteroplasmy, Am. J. Hum. Genet. 46 (1990)
428–433.
[55] I. Trounce, S. Neill, D.C. Wallace, Cytoplasmic transfer of the mtDNA nt 8993 T–NG
(ATP6) point mutation associated with Leigh syndrome into mtDNA-less cells
demonstrates cosegregation with a decrease in state III respiration and ADP/O
ratio, Proc. Natl Acad. Sci. USA 91 (1994) 8334–8338.
[56] R.S. Arnold, C.Q. Sun, J.C. Richards, G. Grigoriev, I.M. Coleman, P.S. Nelson, C.L.
Hsieh, J.K. Lee, Z. Xu, A. Rogatko, A.O. Osunkoya, M. Zayzafoon, L. Chung, J.A.
Petros, Mitochondrial DNA mutation stimulates prostate cancer growth in bone
stromal environment, Prostate 69 (2009) 1–11.
[57] D. Thyagarajan, S. Shanske, M. Vazquez-Memije, D. De Vivo, S. DiMauro, A novel
mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis, Ann.
Neurol. 38 (1995) 468–472.
[58] Y. Shidara, K. Yamagata, T. Kanamori, K. Nakano, J.Q. Kwong, G. Manfredi, H. Oda,
S. Ohta, Positive contribution of pathogenic mutations in the mitochondrial
genome to the promotion of cancer by prevention from apoptosis, Cancer Res. 65
(2005) 1655–1663.
[59] C. van Waveren, Y. Sun, H.S. Cheung, C.T. Moraes, Oxidative phosphorylation
dysfunction modulates expression of extracellular matrix—remodeling genes and
invasion, Carcinogenesis 27 (2006) 409–418.
[60] K. Ishikawa, K. Takenaga, M. Akimoto, N. Koshikawa, A. Yamaguchi, H. Imanishi, K.
Nakada, Y. Honma, J. Hayashi, ROS-generating mitochondrial DNA mutations can
regulate tumor cell metastasis, Science 320 (2008) 661–664.
[61] R.A. Gatenby, R.J. Gillies, Why do cancers have high aerobic glycolysis? Nat. Rev.
Cancer 4 (2004) 891–899.
[62] G. Solaini, A. Baracca, G. Lenaz, G. Sgarbi, Hypoxia and mitochondrial oxidative
metabolism, Biochim. Biophys. Acta 1797 (2010) 1171–1177.
[63] R.B. Hamanaka, N.S. Chandel, Mitochondrial reactive oxygen species regulate
hypoxic signaling, Curr. Opin. Cell Biol. 21 (2009) 894–899.
[64] S.B. Keysar, N. Trncic, S.M. Larue, M.H. Fox, Hypoxia/reoxygenation-induced
mutations inmammalian cells detected by the ﬂow cytometry mutation assay and
characterized by mutant spectrum, Radiat. Res. 173 (2010) 21–26.
[65] C.R. Merril, S. Zullo, H. Ghanbari, M.M. Herman, J.E. Kleinman, L.B. Bigelow, J.J.
Bartko, D.J. Sabourin, Possible relationship between conditions associated with
chronic hypoxia and brain mitochondrial DNA deletions, Arch. Biochem. Biophys.
326 (1996) 172–177.
[66] J. Montoya, E. Lopez-Gallardo, C. Diez-Sanchez, M.J. Lopez-Perez, E. Ruiz-Pesini,
20 years of human mtDNA pathologic point mutations: carefully reading the
pathogenicity criteria, Biochim. Biophys. Acta 1787 (2009) 476–483.[67] R.G. Bristow, R.P. Hill, Hypoxia and metabolism. Hypoxia, DNA repair and genetic
instability, Nat. Rev. Cancer 8 (2008) 180–192.
[68] Y. He, J. Wu, D.C. Dressman, C. Iacobuzio-Donahue, S.D. Markowitz, V.E.
Velculescu, L.A. Diaz Jr., K.W. Kinzler, B. Vogelstein, N. Papadopoulos, Hetero-
plasmic mitochondrial DNA mutations in normal and tumour cells, Nature 464
(2010) 610–614.
[69] H.A. Coller, K. Khrapko, N.D. Bodyak, E. Nekhaeva, P. Herrero-Jimenez, W.G. Thilly,
High frequency of homoplasmic mitochondrial DNA mutations in human tumors
can be explained without selection, Nat. Genet. 28 (2001) 147–150.
[70] J.D. Fackenthal, O.I. Olopade, Breast cancer risk associated with BRCA1 and BRCA2
in diverse populations, Nat. Rev. Cancer 7 (2007) 937–948.
[71] G.D. Dakubo, in: G.D. Dakubo (Ed.), Mitochondrial Genetics and Cancer, Springer,
2010, pp. 119–134.
[72] D.C. Wallace, A mitochondrial paradigm of metabolic and degenerative diseases,
aging, and cancer: a dawn for evolutionary medicine, Annu. Rev. Genet. 39 (2005)
359–407.
[73] T. Kivisild, P. Shen, D.P. Wall, B. Do, R. Sung, K. Davis, G. Passarino, P.A. Underhill, C.
Scharfe, A. Torroni, R. Scozzari, D. Modiano, A. Coppa, P. de Knijff, M. Feldman, L.L.
Cavalli-Sforza, P.J. Oefner, The role of selection in the evolution of human
mitochondrial genomes, Genetics 172 (2006) 373–387.
[74] J.A. Canter, A.R. Kallianpur, F.F. Parl, R.C. Millikan, Mitochondrial DNA G10398A
polymorphism and invasive breast cancer in African-American women, Cancer
Res. 65 (2005) 8028–8033.
[75] V.W. Setiawan, L.H. Chu, E.M. John, Y.C. Ding, S.A. Ingles, L. Bernstein, M.F. Press, G.
Ursin, C.A. Haiman, S.L. Neuhausen, Mitochondrial DNA G10398A variant is not
associated with breast cancer in African-American women, Cancer Genet.
Cytogenet. 181 (2008) 16–19.
[76] M.P. Mims, T.G. Hayes, S. Zheng, S.M. Leal, A. Frolov, M.M. Ittmann, T.M.Wheeler, J.T.
Prchal, Mitochondrial DNA G10398A polymorphism and invasive breast cancer in
African-American women, Cancer Res. 66 (2006) 1880 author reply 1880–1.
[77] K. Darvishi, S. Sharma, A.K. Bhat, E. Rai, R.N. Bamezai, Mitochondrial DNA
G10398A polymorphism imparts maternal haplogroup N a risk for breast and
esophageal cancer, Cancer Lett. 249 (2007) 249–255.
[78] S. Datta, M. Majumder, N.K. Biswas, N. Sikdar, B. Roy, Increased risk of oral cancer
in relation to common Indian mitochondrial polymorphisms and Autosomal
GSTP1 locus, Cancer 110 (2007) 1991–1999.
[79] A.A. Kazuno, K. Munakata, T. Nagai, S. Shimozono, M. Tanaka, M. Yoneda, N. Kato,
A. Miyawaki, T. Kato, Identiﬁcation of mitochondrial DNA polymorphisms that
alter mitochondrial matrix pH and intracellular calcium dynamics, PLoS Genet. 2
(2006) e128.
[80] R.K. Bai, S.M. Leal, D. Covarrubias, A. Liu, L.J. Wong, Mitochondrial genetic
background modiﬁes breast cancer risk, Cancer Res. 67 (2007) 4687–4694.
[81] A.M. Czarnecka, T. Krawczyk, M. Zdrozny, J. Lubinski, R.S. Arnold, W. Kukwa, A.
Scinska, P. Golik, E. Bartnik, J.A. Petros, Mitochondrial NADH-dehydrogenase
subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland,
Breast Cancer Res. Treat. 121 (2010) 511–518.
[82] A. Pezzotti, P. Kraft, S.E. Hankinson, D.J. Hunter, J. Buring, D.G. Cox, The
mitochondrial A10398G polymorphism, interaction with alcohol consumption,
and breast cancer risk, PLoS ONE 4 (2009) e5356.
[83] D. Covarrubias, R.K. Bai, L.J. Wong, S.M. Leal, Mitochondrial DNA variant
interactions modify breast cancer risk, J. Hum. Genet. 53 (2008) 924–928.
[84] E. Ruiz-Pesini, D. Mishmar, M. Brandon, V. Procaccio, D.C. Wallace, Effects of
purifying and adaptive selection on regional variation in human mtDNA, Science
303 (2004) 223–226.
[85] M. Kulawiec, K.M. Owens, K.K. Singh, mtDNA G10398A variant in African-
American women with breast cancer provides resistance to apoptosis and
promotes metastasis in mice, J. Hum. Genet. 54 (2009) 647–654.
[86] J.B. Jones, J.J. Song, P.M. Hempen, G. Parmigiani, R.H. Hruban, S.E. Kern, Detection
of mitochondrial DNA mutations in pancreatic cancer offers a “mass”-ive
advantage over detection of nuclear DNA mutations, Cancer Res. 61 (2001)
1299–1304.
[87] S. Mizutani, Y. Miyato, Y. Shidara, S. Asoh, A. Tokunaga, T. Tajiri, S. Ohta, Mutations
in the mitochondrial genome confer resistance of cancer cells to anticancer drugs,
Cancer Sci. 100 (2009) 1680–1687.
[88] M.E. Gallardo, R. Moreno-Loshuertos, C. Lopez, M. Casqueiro, J. Silva, F. Bonilla, S.
Rodriguez de Cordoba, J.A. Enriquez, m.6267GNA: a recurrent mutation in the
human mitochondrial DNA that reduces cytochrome c oxidase activity and is
associated with tumors, Hum. Mutat. 27 (2006) 575–582.
[89] C. Sun, Q.P. Kong, M.G. Palanichamy, S. Agrawal, H.J. Bandelt, Y.G. Yao, F. Khan, C.L.
Zhu, T.K. Chaudhuri, Y.P. Zhang, The dazzling array of basal branches in the
mtDNA macrohaplogroup M from India as inferred from complete genomes, Mol.
Biol. Evol. 23 (2006) 683–690.
[90] U. Peters, S. Preisler-Adams, C. Lanvers-Kaminsky, H. Jurgens, A. Lamprecht-
Dinnesen, Sequence variations of mitochondrial DNA and individual sensitivity to
the ototoxic effect of cisplatin, Anticancer Res. 23 (2003) 1249–1255.
